Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.

Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05

Ribavirin induced anaemia: the effect of vitamin D supplementation on erythropoietin and erythrocyte indices in normal Wistar rat. Int J Clin Exp Med (2014) 0.87

Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness? Eur J Health Econ (2015) 0.86

Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy. Mediators Inflamm (2015) 0.82

Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes: A Preliminary Report. Gastroenterol Res Pract (2014) 0.79

Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infect Dis Ther (2016) 0.79

Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study. PLoS One (2016) 0.77

Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin. Int J Clin Exp Med (2015) 0.76

The effects of pegylated interferon-α and ribavirin on liver and serum concentrations of activin-A and follistatin in normal Wistar rat: a preliminary report. BMC Res Notes (2015) 0.75

Letter to the editor. J Med Econ (2014) 0.75

An observational study of the direct costs related to hospital admissions, mortality and premature death associated with liver disease in Portugal. BMC Res Notes (2016) 0.75

Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21

Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13

High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology (2004) 2.91

Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut (2010) 2.66

Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol (2004) 2.28

Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72

Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology (2011) 1.62

Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol (2011) 1.60

The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology (2002) 1.57

Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog (2010) 1.51

Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology (2011) 1.49

IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol (2012) 1.47

The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int (2009) 1.46

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis (2007) 1.40

Ultra-sensitive class I tetramer analysis reveals previously undetectable populations of antiviral CD8+ T cells. Eur J Immunol (2004) 1.24

Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One (2012) 1.23

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther (2011) 1.22

The role of cells refractory to productive infection in acute hepatitis B viral dynamics. Proc Natl Acad Sci U S A (2007) 1.19

The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T (2010) 1.15

Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients. J Med Econ (2013) 1.09

The burden of influenza complications in different high-risk groups: a targeted literature review. J Med Econ (2012) 1.05

Impact of alpha interferon and ribavirin on the function of maturing dendritic cells. Antimicrob Agents Chemother (2004) 1.00

Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatr Serv (2010) 0.98

Is there any value to hepatitis B virus genotype analysis? Curr Gastroenterol Rep (2012) 0.98

Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol (2004) 0.96

The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up call. Clin Infect Dis (2012) 0.92

The influence of T cell cross-reactivity on HCV-peptide specific human T cell response. Hepatology (2006) 0.87

Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients. Expert Rev Anti Infect Ther (2010) 0.87

Thyroid dysfunction in a UK hepatitis C population treated with interferon-alpha and ribavirin combination therapy. Clin Endocrinol (Oxf) (2010) 0.86

The surveillance and diagnosis of hepatocellular carcinoma. Eur J Gastroenterol Hepatol (2005) 0.84

A pill for HCV - myth or foreseeable future? Liver Int (2013) 0.83

Forgotten, not neglected: viral hepatitis in resource-limited settings, recall for action. Liver Int (2013) 0.83

Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping. Liver Int (2008) 0.79

Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. Curr Med Res Opin (2010) 0.79

Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany. Hum Vaccin Immunother (2015) 0.78

Darbepoetin alfa therapeutic interchange protocol for anemia in dialysis. Ann Pharmacother (2005) 0.78

Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting. Eur J Heart Fail (2011) 0.78

Management of hepatitis B in pregnant women and infants: a multicentre audit from four London hospitals. BMC Pregnancy Childbirth (2013) 0.78

Treatment-seeking behavior of erectile dysfunction patients in Europe: Results of the Erectile Dysfunction Observational Study. J Sex Med (2006) 0.77

Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml). Liver Int (2014) 0.77

Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C". J Hepatol (2015) 0.77

Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands. Appl Health Econ Health Policy (2014) 0.75

Patient Preference for Dosing Frequency Based on Prior Biologic Experience. J Drugs Dermatol (2017) 0.75